- Trials with a EudraCT protocol (10)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
10 result(s) found for: Drug expiration.
Displaying page 1 of 1.
EudraCT Number: 2020-001818-38 | Sponsor Protocol Number: EFC16750 | Start Date*: 2021-03-02 | |||||||||||
Sponsor Name:Sanofi-Aventis Recherche & Developpement | |||||||||||||
Full Title: Randomized, double-blind, placebo-controlled, parallel-group Phase 3 study to evaluate the efficacy, safety, and tolerability of SAR440340/REGN3500/itepekimab (anti-IL-33 mAb) in patients with mode... | |||||||||||||
Medical condition: Chronic Obstructive Pulmonary Disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BG (Trial now transitioned) CZ (Trial now transitioned) SK (Trial now transitioned) GR (Trial now transitioned) HU (Trial now transitioned) PL (Trial now transitioned) IT (Trial now transitioned) RO (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-001819-24 | Sponsor Protocol Number: EFC16819 | Start Date*: 2021-04-29 | |||||||||||
Sponsor Name:Sanofi-Aventis Recherche & Developpement | |||||||||||||
Full Title: Randomized, double-blind, placebo-controlled, parallel-group Phase 3 study to evaluate the efficacy, safety, and tolerability of SAR440340/REGN3500/itepekimab (anti-IL-33 mAb) in patients with mode... | |||||||||||||
Medical condition: Chronic Obstructive Pulmonary Disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Trial now transitioned) DE (Trial now transitioned) FR (Trial now transitioned) BG (Trial now transitioned) CZ (Trial now transitioned) DK (Completed) HU (Trial now transitioned) PL (Trial now transitioned) PT (Trial now transitioned) LT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-002356-20 | Sponsor Protocol Number: CLI-05993BA1-08 | Start Date*: 2021-05-04 | |||||||||||
Sponsor Name:Chiesi Farmaceutici S.p.A. | |||||||||||||
Full Title: Open label, prospective study to evaluate the effect of step-up from non-extrafine ICS/LABA DPI to extra fine triple therapy with CHF5993 DPI on airway geometry and lung ventilation using FRI in su... | |||||||||||||
Medical condition: COPD (Chronic Obstructive Pulmonary Disease) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) HU (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-002110-22 | Sponsor Protocol Number: LTA-2-2008 | Start Date*: 2008-09-16 | |||||||||||
Sponsor Name:Prof. dr L.H. van den Berg, UMC-Utrecht | |||||||||||||
Full Title: A randomised sequential trial of Lithium in amyotrophic lateral sclerosis | |||||||||||||
Medical condition: Amyotrophic lateral sclerosis (ALS) is a disease characterised by progressive degeneration of motor neurons in brain and spinal cord leading to muscle weakness. ALS can occur at anytime in adulthoo... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-003585-11 | Sponsor Protocol Number: VX16-659-101 | Start Date*: 2017-09-01 | |||||||||||
Sponsor Name:Vertex Pharmaceuticals Incorporated | |||||||||||||
Full Title: A Phase 2, Randomized, Double-blind, Controlled Study to Evaluate the Safety and Efficacy of VX-659 Combination Therapy in Subjects Aged 18 Years and Older With Cystic Fibrosis | |||||||||||||
Medical condition: Cystic fibrosis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IE (Completed) GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-001010-15 | Sponsor Protocol Number: REVC003 | Start Date*: 2019-10-24 | |||||||||||
Sponsor Name:ReViral Ltd. | |||||||||||||
Full Title: A Phase 2a Open-Label Study in Infants with REspiratory Syncytial VIRus Lower RespirAtory Tract Infection, Followed by a DoubLe-blind, Placebo-controlled Part, to Evaluate the Safety, Tolerability,... | |||||||||||||
Medical condition: Respiratory Syncytial Virus Infection | |||||||||||||
|
|||||||||||||
Population Age: Newborns, Infants and toddlers, Children, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Prematurely Ended) PL (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-000364-15 | Sponsor Protocol Number: SUNRISE-CRC | Start Date*: 2019-09-11 |
Sponsor Name:VU University Medical Center, Department of Medical | ||
Full Title: A randomized phase II/III study of pulsatile high-dose sunitinib versus TAS-102 in patients with metastatic colorectal carcinoma (mCRC). | ||
Medical condition: Advanced colorectal tumors | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2009-014735-20 | Sponsor Protocol Number: MI-CP219 | Start Date*: 2009-12-29 | |||||||||||
Sponsor Name:MedImmune Ltd | |||||||||||||
Full Title: A Phase 2 Randomised, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study to Evaluate the Efficacy and Safety of CAM-3001 in Subjects with Rheumatoid Arthritis | |||||||||||||
Medical condition: Rheumatoid Arthritis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: LV (Completed) EE (Completed) HU (Completed) CZ (Completed) LT (Completed) PL (Completed) BG (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-023342-67 | Sponsor Protocol Number: C38072/3081 | Start Date*: 2011-07-20 | |||||||||||
Sponsor Name:Teva Branded Pharmaceutical Products R&D, Inc. | |||||||||||||
Full Title: A 16-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Reslizumab (0.3 or 3.0 mg/kg) as Treatment for Patients (12-75 Years of Age) wit... | |||||||||||||
Medical condition: Treatment for patients with eosinophilic asthma | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) SE (Completed) HU (Completed) NL (Completed) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-001077-40 | Sponsor Protocol Number: T54/2015 | Start Date*: 2019-05-07 |
Sponsor Name:Turku University Hospital | ||
Full Title: INNOVATIVE STEROID TREATMENT TO REDUCE ASTHMA DEVELOPMENT IN CHILDREN AFTER FIRST-TIME RHINOVIRUS INDUCED WHEEZING – THE INSTAR STUDY | ||
Medical condition: First acute wheezing episode | ||
Disease: | ||
Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | |
Trial protocol: FI (Trial now transitioned) NO (Trial now transitioned) SE (Trial now transitioned) | ||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
